Tim Smith

These phase 3 data on delgocitinib cream (Anzupgo) 20 mg/g highlight the drug’s potential for adolescents aged 12 years and older with chronic hand eczema (CHE).

Kernizan discusses winning the 2024 Society for Pediatric Dermatology Medical Student Mentorship Award and getting into pediatric dermatology as a student.

In this analysis, investigators demonstrated that risankizumab led to improvements in palmoplantar pustulosis (PPP) that continued through to Week 68.

These data point to the necessity of quality and usability when using smartphone photographs of skin conditions in emergency departments.

In this interview, Druskovich highlights her experiences being mentored through the Society for Pediatric Dermatology’s Medical Student Mentorship Award.

These data highlight the unique burdens faced by patients with generalized pustular psoriasis (GPP) compared to those of patients with psoriasis vulgaris.

These data provide a potential option for those suffering from hidradenitis suppurativa, as off-label treatment with botulinum toxin type X led to positive findings in patients.

These data point to increasing omega-3 consumption as a potential preventive strategy against atopic dermatitis.

In this analysis, investigators sought evaluate the effectiveness and safety of adding low-dose oral minoxidil to the standard anti-inflammatory treatment of lichen planopilaris.

These data suggest that psoriasis treatment algorithms may benefit younger patients if they implement a step-down rather than step-up approach to biologic use.

These findings highlight the prevalence of atopic dermatitis among adults in France, as well as the different factors associated with various disease profiles.

These phase 3 findings from the INTEGUMENT-PED clinical trial highlight the efficacy and safety of roflumilast cream 0.05% for pediatric patients with atopic dermatitis.

Investigators in China developed a patch test designed for hair care products tailored to clinical needs such as those of patients with conditions like alopecia areata.

These data suggest therapeutic modulation of IL-23 inhibitors for psoriasis in those who have shown stability may be a legitimate strategy to ensure efficacy and safety.

These data were the result of a new network meta-analysis looking specifically at children with eczema, highlighting the hierarchy of effectiveness among systemic drugs.

Alpyn’s Investigational New Drug application’s clearance by the FDA for the new Zabalafin Hydrogel for atopic dermatitis follows positive phase 2a clinical findings.

This genome-wide meta-analysis demonstrated that changes in 2 parts of the genome both work to influence patients’ risk of frontal fibrosing alopecia (FFA).

In this feature, 3 experts highlight their own research on new technological advances and their views on the benefits and drawbacks of artificial intelligence in dermatology.

This analysis highlights the major risk factors resulting in limited use of oral JAKi for patients with hidradenitis suppurativa, including smoking, obesity, hypertension, and age.

The February 18, 2025 SOCS News Update highlights SOCS mentorship opportunities as well as the importance of mentors and role models.

The FDA decision to approve the supplemental biologics license application for dupilumab (Dupixent) follows recent pivotal clinical trial data assessing 106 patients.

This analysis highlights the efficacy and safety of abrocitinib among patients with atopic dermatitis in China, as well as the medication’s impact on patients’ blood biomarkers.

These findings from the POETYK-PSO long-term extension trial point to a lack of new safety concerns in the first 5 years of using deucravacitinib for psoriasis.

These data expand upon existing literature on pediatric HS and racial differences among patients based on management, presentation, and severity.

These data highlight deucravacitinib’s impact among patients with psoriasis who are biologic- and apremilast-naive and those with prior histories with these treatments.

In this retrospective analysis, orally administered tofacitinib was shown to be efficacious among younger patients with alopecia areata due to regrowth results.

This approval by the FDA of Evolus’s 2 new hyaluronic acid gels provides an additional set of options for dermatologists in the aesthetic products market.

These data highlight a variety of comorbidities linked to dermatologic diseases in children with obesity, including common comorbidities such as asthma.

This interview highlights the significance of Bruckner’s recent phase 3 data on birch triterpenes as a potential treatment for dystrophic and junctional EB, as well as patients’ unmet needs.

Bruckner discusses her team’s long-term data on the safety and efficacy of birch bark extract, also known as Oleogel-S10, for those with epidermolysis bullosa.